Overview
Biopharmaceutical firm's Q4 net loss widened to $44.9 mln from $33.5 mln a year ago
Company advancing Phase 3 HCV program, with results expected in 2026
Expanded antiviral pipeline with new HEV program, clinical trials start mid-2026
Outlook
Company anticipates mid-2026 topline results from North American HCV trial
Atea plans to start HEV clinical development mid-2026
Company expects year-end 2026 results from HCV trial outside North America
Result Drivers
R&D EXPENSES - Rose to $47.8 mln from $25.7 mln, partially driven by an increase in external spend for HCV Phase 3 clinical development including the purchase of comparator drug and expense related to the achievement of a milestone under the Merck license agreement
INCOME TAX BENEFIT - Co recorded benefit of $6.8 mln due to recognition of previously unrecognized tax benefits following a lapse in the statute of limitations
Company press release: ID:nGNXkwGB8
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Income | -$44.87 mln | ||
Q4 Basic EPS | -$0.57 | ||
Q4 Operating Expenses | $54.93 mln | ||
Q4 Operating Income | -$54.93 mln | ||
Q4 Pretax Profit | -$51.64 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $6.00, about 20.5% above its March 4 closing price of $4.98
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments